SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Tuesday reported a loss of $31.2 million in its fourth quarter.

The Salt Lake City-based company said it had a loss of 36 cents per share. Earnings, adjusted for non-recurring costs and stock option expense, were 4 cents per share.

The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of 2 cents per share.

The molecular diagnostic company posted revenue of $196.6 million in the period, also topping Street forecasts. Five analysts surveyed by Zacks expected $194.3 million.

For the year, the company reported a loss of $263.3 million, or $3.18 per share. Revenue was reported as $753.2 million.

Myriad expects full-year revenue in the range of $820 million to $840 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MYGN at https://www.zacks.com/ap/MYGN

For copyright information, check with the distributor of this item, STATS Perform dba Automated Insights. , source Associated Press News